Jay A. Lefton
Jay A. Lefton
(416) 865-5454
(416) 364-7813
333 Bay St, Suite 2400, Bay Adelaide Ctr, Box 20, Toronto, ON
Year called to bar: 1983 (ON)
Jay Lefton practises corporate and securities law. Jay advises clients on public and private mergers & acquisitions transactions, private equity matters and public and private financings, as well as assisting with strategic alliances, technology transfer and licensing. He works predominantly in the technology and life sciences sector. Assisting acquirers and target companies and their boards of directors, Jay advises on negotiated transactions and unsolicited takeover bids, most of which are multi-jurisdictional. Jay also represents issuers, both public and private, as well as advisers, venture capitalists, institutional investors and private equity funds. Working with universities, hospitals, research institutions and researchers, Jay advises at various stages in the commercialization of their discoveries. Jay takes a leading role in the firm’s Israeli and West Bank initiative, and travels to the region several times a year. Jay is a former member of the Ontario Securities Commission's Securities Advisory Committee, advising the Commission on various matters, including legislative and policy initiatives. Jay was an adjunct faculty member at Toronto’s Osgoode Hall Law School and has also instructed at the Rotman School of Management at the University of Toronto.
Jay A. Lefton is a featured Leading Lawyer in:
Canadian Legal Lexpert Directory
Consistently Recommended
Canadian Legal Lexpert Directory
Repeatedly Recommended
Jay A. Lefton is also listed in the following publication(s)
Read more about Jay A. Lefton in ...
On March 1, 2016, Moody’s Analytics, Inc., a wholly owned subsidiary of Moody’s Corporation, acquired GGY Consulting, a leading provider of advanced actuarial software for the global life insurance industry.
On January 15, 2016, Manitoba Telecom Services Inc. (MTS) (TSX: MBT) completed the sale of its Allstream division to Zayo Group, LLC (Zayo), a leading provider of communications infrastructure and network-neutral colocation and connectivity, in an all cash transaction for $465 million.
On April 7, 2015, Trillium Therapeutics Inc. completed its underwritten public offering of common shares and Series II non-voting convertible first preferred shares in the United States.